May 2015 Blog Posts (8)

Ongoing Trials Show Positive Data for ONT-380 in HER2-Positive Breast Cancer

Results from an ongoing multiple clinical studies with ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer being developed by Seattle-based Oncothyreon, shows that the trial drug is well tolerated in Phase Ib trials.

These results of the trials were presented during the annual meeting of the American Society of Clinical Oncology (ASCO) being held May 29 - June 2,…

Continue

Added by Editorial Team on May 30, 2015 at 5:30pm — No Comments

Scale to Stratify the Magnitude of Clinical Benefit of Anti-cancer Medicines Announced by European Society for Medical Oncology

Earlier today ESMO, the European Society for Medical Oncology, the leading European professional organisation committed to advancing the specialty of medical oncology and promoting an integrated approach to cancer treatment and care, announced the publication of the ESMO Magnitude of Clinical Benefit Scale or ESMO-MCBS[1], a new tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.

One of the reasons of the development…

Continue

Added by Editorial Team on May 30, 2015 at 10:30am — No Comments

Exposure to Aflatoxin linked to Gallbladder Cancer

In a small study in Chile that included patients with gallbladder cancer, exposure to aflatoxin (a toxin produced by mold) was associated with an increased risk of gallbladder cancer, according to a study in the May 26, 2015 issue of JAMA - The Journal of the American medical Association. [1]

In Chile, gallbladder cancer is a leading cause of cancer death in women. Exposure to aflatoxin, a liver carcinogen, is associated with gallbladder cancer in primates. Aflatoxin…

Continue

Added by Editorial Team on May 26, 2015 at 11:30am — No Comments

How Attitudes and Beliefs about Complementary and Alternative Medicine (CAM) Predict Acceptance Among Patients with Cancer

Complementary and alternative medicine or CAM is a term for generally used to describe medical products, practices and services that are not part of standard medical care. While complementary medicine are treatments that are used along with standard medical treatments, they are, however, not considered to be standard treatments. One example is using acupuncture to help lessen and reduce some side effects of cancer treatment. On the other had, alternative medicine are treatments that…

Continue

Added by Editorial Team on May 26, 2015 at 10:30am — No Comments

Cancer Care Management: A Good News, Bad News Scenario

By Paul Keckley, Ph.D., Navigant Healthcare

In cancer care management, there’s plenty of good news, and some bad news. The good news is that advances in diagnosis and treatments are working: a diagnosis of cancer is no longer a death sentence, The bad news is that the costs for these advances are prompting many to…

Continue

Added by Editorial Team on May 19, 2015 at 11:00am — No Comments

Parents' Decision-making in HPV Vaccination for their Daughters

The Human Papillomavirus (HPV) is a leading cause of sexually transmitted diseases. More than 70% of sexually active people getting the virus at least once in their lifetimes. Persistent infection with some HPV strains can lead to cervical cancer, the second most common cancer in women, as well as to head-and-neck and other types of cancer and anogenital warts in both men and women.

Controversy

Current HPV vaccines have been shown to be safe and virtually 100%…

Continue

Added by Editorial Team on May 12, 2015 at 3:00pm — No Comments

Ovarian Cancer Screening Could Herald Radical dDeparture from other Cancer Screening Tests, UK Collaborative Trial Shows

The diagnosis of ovarian cancer is complex and has a high "case-fatality" ratio. Most women are not diagnosed until the disease is in its advanced stages.[1]

Interim results from a 14-year study by the UK Collaborative Trial of Ovarian Cancer Screening, also known as UKCTOCS, is a large randomized controlled clinical trial conducted in the United Kingdom, shows that ovarian cancer screening could herald a radical departure established by other cancer screening tests used…

Continue

Added by Editorial Team on May 11, 2015 at 5:30pm — No Comments

First Patient Randomized in Pivotal Phase III Melanoma Immunotherapy - Intus - Clinical Trial

Melanoma, one of the most lethal skin cancers which originates in pigment-producing cells known as melanocytes, is often caused by unrepaired DNA damage to skin cells from UV radiation.

Patients who have progressed to stage IV melanoma have a cancer that has metastasized—or spread—to distant sites in the body such as the lymph nodes, lungs, liver or brain. As a result, advanced melanoma is exceedingly difficult to treat, with a five-year survival rate of approximately 15%. There are…

Continue

Added by Editorial Team on May 1, 2015 at 12:00am — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+